Frequency of creatine kinase elevation during treatment with fluvastatin

被引:31
作者
Benghozi, R
Bortolini, M
Jia, Y
Isaacsohn, JL
Troendle, AJ
Gonasun, L
机构
[1] Novartis Pharmaceut, E Hanover, NJ 07936 USA
[2] Novartis Pharma Ltd, Basel, Switzerland
[3] Medpace LLC, Cincinnati, OH USA
关键词
D O I
10.1016/S0002-9149(01)02209-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) have become the most frequently prescribed agents for the treatment of hyper-cholesterolemia because of the compelling evidence of their effect on reducing cardiovascular event rates.(1.2) They are generally well tolerated and have a favorable safety profile. Although rare, a major adverse event of statins is myopathy, defined as creatine kinase (CK) increase to greater than or equal to10 times the upper limit of normal (ULN) with accompanying symptoms of muscle pain or weakness.(3) If the myopathy is not recognized and drug therapy continues, rhabdomyolysis and acute renal failure may result. Statin treatment is always long term, and thus, attention to the possibility of myopathy continues to be important. There may be significant differences in the frequency of myopathy and/or CK elevations associated with different statins. This study used a pooled analysis to evaluate the frequency of CK elevation associated with fluvastatin treatment.
引用
收藏
页码:231 / +
页数:4
相关论文
共 9 条
[1]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[2]   Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin [J].
Gruer, PJK ;
Vega, JM ;
Mercuri, MF ;
Dobrinska, MR ;
Tobert, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (07) :811-815
[3]   Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]) [J].
Herd, JA ;
Ballantyne, CM ;
Farmer, JA ;
Ferguson, JJ ;
Jones, PH ;
West, S ;
Gould, KL ;
Gotto, AM .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (03) :278-286
[4]   Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial [J].
Insull, W ;
Isaacsohn, J ;
Kwiterovich, P ;
Ma, P ;
Brazg, R ;
Dujovne, C ;
Shan, M ;
Shugrue-Crowley, E ;
Ripa, S ;
Tota, R .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2000, 28 (02) :47-68
[5]   Current perspectives on statins [J].
Maron, DJ ;
Fazio, S ;
Linton, MF .
CIRCULATION, 2000, 101 (02) :207-213
[6]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[7]   The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment [J].
Riegger, G ;
Abletshauser, C ;
Ludwig, M ;
Schwandt, P ;
Widimsky, J ;
Weidinger, G ;
Welzel, D .
ATHEROSCLEROSIS, 1999, 144 (01) :263-270
[8]   RATIONALE AND DESIGN OF A SECONDARY PREVENTION TRIAL OF LOWERING NORMAL PLASMA-CHOLESTEROL LEVELS AFTER ACUTE MYOCARDIAL-INFARCTION - THE CHOLESTEROL AND RECURRENT EVENTS TRIAL (CARE) [J].
SACKS, FM ;
PFEFFER, MA ;
MOYE, L ;
BROWN, LE ;
HAMM, P ;
COLE, TG ;
HAWKINS, CM ;
BRAUNWALD, E .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (15) :1436-1446
[9]   A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty - Final results of the fluvastatin angiographic restenosis (FLARE) trial [J].
Serruys, PW ;
Foley, DP ;
Jackson, G ;
Bonnier, H ;
Macaya, C ;
Vrolix, M ;
Branzi, A ;
Shepherd, J ;
Suryapranata, H ;
de Feyter, PJ ;
Melkert, R ;
van Es, GA ;
Pfister, PJ .
EUROPEAN HEART JOURNAL, 1999, 20 (01) :58-69